AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03397706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRx-3996
Description: Taken orally once or twice daily
Study NCT03397706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Taken orally once or twice daily
Study NCT03726125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - SC
Description: Administered SC
Study NCT03726125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec - SC
Description: Administered SC
Study NCT03726125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3374849 - IV
Description: Administered IV
Study NCT00022698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00022698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT03726125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec - IV
Description: Administered IV
Study NCT04960436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscus Allograft Transplantation
Description: patients received surgery of Meniscus Allograft Transplantation
Study NCT04960436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meniscectomy
Description: patients received surgery of Meniscectomy
Study NCT04147091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApaCare & Repair
Description: Initial cariuos lesions were treated.
Study NCT04171258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: Experimental
Study NCT04171258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Active Comparator
Study NCT01861652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Health Systems Vasculaire Leg Compression Device
Description: Leg (calf) compression device used to alleviate symptoms of restless legs
Study NCT01762436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoprolol
Study NCT01762436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Study NCT00550745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
Study NCT00550745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: single 0.65 mL Placebo injection. 6 month treatment period.
Study NCT00879476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10mg capsules
Study NCT00879476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10mg capsules
Study NCT02425566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
Study NCT02425566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
Study NCT01864551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Study NCT01864551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study NCT00607074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Study NCT00607074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Giardia treatment only (secnidazole or albendazole)
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Study NCT00607074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (placebo)
Description: Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Study NCT00078767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: 12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
Study NCT00078767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Pill
Description: 12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
Study NCT00078767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline Pill
Description: 12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
Study NCT00078767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
Study NCT04076293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
Study NCT04076293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
Study NCT02088905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy
Description: Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
Study NCT00291876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 doses at 12 months interval
Study NCT03348007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking two kinds of mineral water
Description: 1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
Study NCT03348007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taking two kinds of mineral water
Description: 1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
Study NCT00940823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed FP7 Valve
Description: Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
Study NCT00940823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt-350 Tube
Description: Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
Study NCT03395145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
Description: Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
Study NCT04527289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine (100mg) as add on therapy.
Description: Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
Study NCT04527289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will be managed with placebo as add on to the standard regimen.
Study NCT01377350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumedicares monitoring system.
Description: 50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
Study NCT01377350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumedicares monitoring system
Description: Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
Study NCT02763137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard LD/CD
Description: LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
Study NCT01099904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: multiple oral doses for 5 days
Study NCT02763137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semi continuous intra-oral administration of LD/CD
Description: Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
Study NCT02158013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Levorag Emulgel
Study NCT02158013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Study NCT03986112 — intervention group
Intervention type: BIOLOGICAL
Intervention: carotid sonography and inferior vena cava sonography
Description: Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
Study NCT02119416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration first
Description: All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
Study NCT02119416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Caffeine Administration first (1mg/kg body weight)
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
Study NCT02119416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Caffeine Administration first (2mg/kg body weight)
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
Study NCT02363556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered vaginally
Study NCT02363556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered buccally
Study NCT02363556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered vaginally with Dilapan
Study NCT02363556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misoprostol administered buccally with Dilapan
Study NCT03630874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the impact of a prescription support tool
Description: From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided.
Study NCT01936584 — intervention group
Intervention type: PROCEDURE
Intervention: TAPP repair for inguinal hernias
Study NCT01936584 — intervention group
Intervention type: PROCEDURE
Intervention: TEP repair for inguinal hernia
Study NCT01936584 — intervention group
Intervention type: OTHER
Intervention: EuraHS-QoL questionnaire
Description: questionnaire administration
Study NCT01936584 — intervention group
Intervention type: OTHER
Intervention: Carolina Comfort Scale
Description: questionnaire administration
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARC-520
Study NCT03838289 — intervention group
Intervention type: RADIATION
Intervention: multimodal magnetic resonance imaging or computed tomography
Description: multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
Study NCT02815332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01 1% Minocycline Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks
Study NCT02815332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01 2% Minocycline Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks
Study NCT02815332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPX-01 Vehicle Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks
Study NCT00846248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
Study NCT00846248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chromium
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
Study NCT00846248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
Study NCT02215395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NES/EE CVR
Description: Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Study NCT02951208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
Study NCT02951208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active VR Motivation Training
Description: Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
Study NCT02951208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
Study NCT02951208 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham VR Motivation Training
Description: Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
Study NCT02693470 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab
Description: 50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
Study NCT03416426 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer® PFO occluder or Gore® Septal Occluder
Description: The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
Study NCT00813150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
Study NCT00813150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
Study NCT00813150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
Study NCT00813150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
Study NCT00813150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
Study NCT01405339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Atomization Device (MAD)
Description: The use of pulmicort via MAD once a day for a total of 30 days.
Study NCT01405339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide via Nasal Syringe
Description: The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
Study NCT03620305 — intervention group
Intervention type: OTHER
Intervention: Description of treatment of septic pseudarthrosis
Description: description of chirurgical 2 steps management of septic pseudarthrosis
Study NCT01408381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
Study NCT03563352 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attend an interview
Study NCT03563352 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03484663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter (small catheter drainage)
Description: Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
Study NCT01475708 — intervention group
Intervention type: DRUG
Intervention: Doxycycline
Description: 100 mg PO bid, 14 days
Study NCT04891146 — intervention group
Intervention type: OTHER
Intervention: Systemic inflammatory immmune index
Description: Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
Study NCT01579422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social cognitive training
Description: social cognitive training, 8-10 sessions